Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
NEW YORK, Jan. 22, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Vital Therapies, Inc. (NASDAQ: VTL) securities from April 17, 2014 through August 21, 2015 all dates inclusive (the “Class Period”) of the February 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Vital Therapies investors under the federal securities laws.
To join the Vital Therapies class action, go to the website at http://www.rosenlegal.com/cases-671.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose material information regarding Vital Therapies’ ELAD System studies, VTI-208, VTI-210, and VTI-212, including: (1) the studies’ independent significance; (2) the degree to which the studies were interrelated; and (3) that in the case of the failure of the VTI-208 trial, Vital Therapies would not continue the VTI-210 trial. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-671.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] www.rosenlegal.com
